Home / Health / Ningxia's First Half-Match Transplant Saves Leukemia Patient
Ningxia's First Half-Match Transplant Saves Leukemia Patient
11 Jun
Summary
- Ningxia's first haploidentical stem cell transplant was successfully performed.
- A 28-year-old leukemia patient has recovered after the groundbreaking procedure.
- The breakthrough offers advanced treatment locally for severe blood disorders.
The Ningxia Hui autonomous region has successfully performed its first haploidentical allogeneic hematopoietic stem cell transplant, a procedure also known as a haplo transplant. This significant medical achievement allows patients with severe blood disorders to receive advanced care locally.
A 28-year-old leukemia patient, diagnosed in October 2025, has recovered and been discharged after undergoing the specialized transplant. Unable to find a fully matched donor, her medical team utilized a partially matched relative as a donor, a complex procedure that requires overcoming increased risks of complications.
This groundbreaking operation, conducted at the General Hospital of Ningxia Medical University with collaboration from the Peking University Institute of Hematology, fills a critical gap in Ningxia's medical capabilities. It offers renewed hope for patients suffering from leukemia, anemia, and other serious blood diseases.
The successful implementation of haplo transplants is expected to reduce treatment costs and travel burdens for patients in Ningxia and surrounding regions. This advancement ensures broader access to life-saving therapies, marking a new era in regional healthcare.
